Hanyang University   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Seoul Korea, Republic of (1939)

Organization Overview

First Clinical Trial
1996
NCT01393665
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Department of Anesthesiology and Pain Medicine, Hanyang University Hospital | Department of Internal Medicine, Hanyang University | Department of Rhumatology in Hanyang University Medical Center | Hanyang University | Hanyang University College of Medicine | Hanyang University College of Medicine & Hanyang University Guri Hospital | Hanyang University College of Medicine & Hanyang University Seoul Hospital | Hanyang University Guri Hospital, Guri, Kyunggi-do, Korea, Republic of | Hanyang University Guri Hospitall | Hanyang University Hospital for Rheumatic Diseases | Hanyang University Seoul Hospital | Hanyang Universtiy Hospital of Korea | Hanyang Univ. Guri Hospital | Hyun Young Kim | swroh@hanyang.ac.kr | The Hanyang Universitiy Guri Hospital | Wuhan Hanyang Hospital

Active Ingredients

Drugs in Phase 4 Trials (34)

5,7-dihydroxy-3',4',6-trimethoxyflavone (2 trials)

acetylsalicylic acid (aspirin) (2 trials)

adalimumab (humira) (1 trial)

amantadine (symmetrel) (1 trial)

amino acids (Freamine) (1 trial)

bazedoxifene (Duavee) (1 trial)

calcium (1 trial)

cilostazol (pletal) (1 trial)

cyproviron (1 trial)

dobesilic acid (1 trial)

entecavir (baraclude) (3 trials)

esomeprazole (nexium) (2 trials)

etanercept (enbrel) (2 trials)

glimepiride (amaryl) (2 trials)

golimumab (simponi) (1 trial)

hifenac (1 trial)

imotun (1 trial)

infliximab (remicade) (3 trials)

insulin human (humulin) (1 trial)

lamivudine (epivir) (1 trial)

limaprost (1 trial)

misoprostol (cytotec) (1 trial)

motilitone (2 trials)

nateglinide (starlix) (1 trial)

pantoprazole (protonix) (1 trial)

pitavastatin (livalo) (1 trial)

polyethylene glycol (1 trial)

pregabalin (lyrica) (1 trial)

sitagliptin (januvia) (1 trial)

sodium chloride (2 trials)

sugammadex (bridion) (1 trial)

tolvaptan (samsca) (1 trial)

vitamin d3 (2 trials)

vitis vinifera (1 trial)

Drugs in Phase 3 Trials (36)

ag npp709 (Synatura) (1 trial)

allogenic human chondrocytes expressing transforming growth factor-β1 (1 trial)

amlodipine (norvasc) (3 trials)

besifovir (1 trial)

Biphenyl Dimethyl Dicarboxylate (2 trials)

capecitabine (xeloda) (1 trial)

carvedilol (coreg) (1 trial)

ckd-825 (1 trial)

fimasartan (kanarb) (5 trials)

gemcitabine (gemzar) (1 trial)

gimeracil (1 trial)

glycine (1 trial)

gv 1001 (1 trial)

hydrochlorothiazide (esidrix) (2 trials)

immuncell-lc (1 trial)

interferon alpha-2b (Intron-A) (1 trial)

lansoprazole (prevacid) (1 trial)

lenzumestrocel (1 trial)

losartan (cozaar) (1 trial)

moxifloxacin (avelox) (1 trial)

olmesartan (benicar) (1 trial)

oteracil (1 trial)

pegylated-interferon (1 trial)

pranlukast (Onon) (1 trial)

pyrus pyrifolia extract (1 trial)

rebamipide (1 trial)

recoflavone (1 trial)

riluzole (rilutek) (1 trial)

rituximab (rituxan) (3 trials)

tamsulosin (flomax) (1 trial)

tegafur (1 trial)

tegoprazan (1 trial)

tenofovir (viread) (1 trial)

umbilical cord mesenchymal stem cells (1 trial)

valsartan (diovan) (1 trial)

zabofloxacin (1 trial)

Drugs in Phase 2 Trials (22)

acamprosate (campral) (1 trial)

acetaminophen (tylenol) (1 trial)

allogeneic hematopoietic stem cells (Hemacord) (4 trials)

autologous umbilical cord blood (1 trial)

bone marrow derived mesenchymal stem cells (2 trials)

celecoxib (celebrex) (1 trial)

cortisone acetate (cortone) (1 trial)

duloxetine (Cymbalta) (1 trial)

epoetin (Epogen) (1 trial)

idarubicin (idamycin) (1 trial)

melissa officinalis (1 trial)

naloxone (narcan) (1 trial)

naproxen (naprosyn) (1 trial)

oxycodone (oxycontin) (1 trial)

peripheral blood lymphocytes (1 trial)

rivaroxaban (xarelto) (1 trial)

rocuronium (zemuron) (1 trial)

sargramostim (leukine) (2 trials)

thiamine (1 trial)

tramadol (Ultram) (1 trial)

vitamin c (1 trial)

vortioxetine (trintellix) (1 trial)

Drugs in Phase 1 Trials (3)

da-3030 (1 trial)

folic acid (1 trial)

naltrexone (revia) (1 trial)

Drugs in Other Trials (10)

asunaprevir (1 trial)

citron peel extract (1 trial)

daclatasvir (daklinza) (1 trial)

Fexuprazan (1 trial)

ginseng (1 trial)

icosapent ethyl (vascepa) (1 trial)

midazolam (versed) (1 trial)

propofol (diprivan) (1 trial)

rivastigmine (exelon) (1 trial)

tofacitinib (xeljanz) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alcohol Drinking (Phase 2)

Alcoholism (Phase 2)

Amyotrophic Lateral Sclerosis (Phase 2)

Arthritis (Phase 3)

Arthritis, Juvenile (Phase 3)

Arthritis, Psoriatic (Phase 3)

Arthritis, Rheumatoid (Phase 4)

Ascites (Phase 4)

Atrial Fibrillation (Phase 3)

Bronchitis (Phase 3)

Central Nervous System Diseases (Phase 1)

Cerebral Palsy (Phase 2)

Chronic Pain (Phase 2)

Constriction, Pathologic (Phase 4)

Depression (Phase 2)

Depressive Disorder (Phase 2)

Depressive Disorder, Major (Phase 2)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Diabetic Neuropathies (Phase 1)

Diabetic Retinopathy (Phase 4)

Dyspepsia (Phase 4)

Esophagitis (Phase 3)

Essential Hypertension (Phase 3)

Fatty Liver (Phase 2)

Gastritis (Phase 3)

Gastroesophageal Reflux (Phase 4)

Glioblastoma (Phase 3)

Heart Arrest (Phase 2)

Hepatitis (Phase 4)

Hepatitis A (Phase 4)

Hepatitis B (Phase 4)

Hepatitis B, Chronic (Phase 4)

Hepatitis C (Phase 4)

Hepatitis C, Chronic (Phase 4)

Hepatitis, Chronic (Phase 4)

Hypercholesterolemia (Phase 4)

Hyperplasia (Phase 3)

Hypertension (Phase 3)

Hyponatremia (Phase 4)

Hypothermia (Phase 4)

Infections (Phase 3)

Intermittent Claudication (Phase 4)

Leukemia (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Liver Diseases (Phase 4)

Lung Diseases (Phase 3)

Lung Diseases, Obstructive (Phase 3)

Lupus Nephritis (Phase 1)

Metabolic Syndrome (Phase 4)

Motor Neuron Disease (Phase 2)

Nephritis (Phase 1)

Nerve Degeneration (Phase 2)

Nervous System Diseases (Phase 1)

Neuralgia (Phase 2)

Neurodegenerative Diseases (Phase 1)

Neuromuscular Diseases (Phase 1)

Non-alcoholic Fatty Liver Disease (Phase 2)

Osteoarthritis (Phase 4)

Osteoarthritis, Knee (Phase 4)

Out-of-Hospital Cardiac Arrest (Phase 2)

Pancreatic Neoplasms (Phase 3)

Parkinson Disease (Phase 4)

Prostatic Hyperplasia (Phase 3)

Pulmonary Disease, Chronic Obstructive (Phase 3)

Respiratory Tract Infections (Phase 3)

Retinal Diseases (Phase 4)

Rhinitis (Phase 3)

Rhinitis, Allergic (Phase 3)

Rhinitis, Allergic, Perennial (Phase 3)

Sclerosis (Phase 2)

Spinal Stenosis (Phase 4)

Spondylitis (Phase 3)

Spondylitis, Ankylosing (Phase 3)

Stomach Neoplasms (Phase 3)

Syndrome (Phase 4)

Thromboembolism (Phase 2)

Venous Thromboembolism (Phase 2)

Wounds and Injuries (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 80
  • # of Trial APIs: 105